Search 

China innovative drug R&D company

BioChange is a biotech startup in tissue engineering and regenerative medicine. Our main product is a gelatin based injectable scaffold.

BioChange has developed CellFoam™ , a unique injectable cell adhesive-scaffold that stimulates guided tissue regeneration and supports cell seeding. When CellFoam is injected as stand alone, it completely degrades within the body after about 3 months of a remodeling phase, as new functional tissue is formed, replacing the aged or impaired tissue.

Our first human product is a therapy for skin ageing (BlueStim™ product), it modulates fibroblasts' behavior to regenerate new collagen, regaining skin thickness and quality. In other words, it turns aged skin to young.

The core technology can fit various applications in healthcare such as COPD, macular degeneration, neural repair, periodontal disease, and tissue bioprinting.

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and health care centers.

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.

Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.

The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.

Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.

Investor

Chengdu Kanghong Pharmaceutical Co., Ltd. is a pharmaceutical company integrating R & D and production. Kanghong has involved in the fields of traditional Chinese medicine, chemical medicine, biological medicine and medical devices. One of the products- conbercept, first in class has been developing in more than 30 countries in the world.

China Meheco Group Co.,Ltd is a state holding company listed at Shanghai Stock Exchange (Stock No. 600056).

China Meheco is a domestic leading distributor of pharmaceutical and health care products in China, and it has strong terminal network coverage. Pharmaceutical business has been maintaining a rapid development over the years, and it is an important development force in China.